⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL842714 | 1.00 | — | — | |
| SCHEMBL4528459 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL25286260 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL899324 | 0.97 | — | — | |
| Trifluoroacetic Acid SCHEMBL18342198 | 0.87 | CYP2D6 (0.50) | — | |
| SCHEMBL10563100 | 0.84 | CYP2D6 (0.52) | — | |
| Butylamine SCHEMBL18109637 | 0.82 | CYP2D6 (0.45) | — | |
| SCHEMBL30176231 | 0.81 | CYP2D6 (0.40) | — | |
| SCHEMBL20956354 | 0.80 | CYP2D6 (0.58) | — | |
| SCHEMBL3367600 | 0.80 | CYP2D6 (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3686182-A1 | CHEMICALLY ACTIVATED WATER-SOLUBLE PRODRUG | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2020-07-29 | — | — | EP | claimed |
| US-20200207782-A1 | CHEMICALLY ACTIVATED WATER-SOLUBLE PRODRUG | SUMITOMO DAINIPPON PHARMA CO., LTD (JP) | 2020-07-02 | — | — | US | claimed |
| US-11998610-B2 | Conjugates and methods of using the same | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| WO-2024044731-A1 | DIAZEPINO-THIENO-QUINOXALINE COMPOUNDS AND THEIR USE IN THERAPY | MATCHPOINT THERAPEUTICS INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2023244817-A1 | SUBSTITUTED PIPERIDINES AS CK1A DEGRADERS | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| US-20230287003-A1 | BCL6 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-09-14 | — | — | US | disclosed |
| EP-3654968-B1 | METALLO-BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-08-16 | — | — | EP | disclosed |
| US-20230203043-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-06-29 | — | — | US | disclosed |
| EP-4201939-A1 | BCL6 INHIBITORS | Cancer Research Technology Limited (GB) | 2023-06-28 | — | — | EP | disclosed |
| US-11655260-B2 | Heterocyclic compounds as arginase inhibitors | GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) | 2023-05-23 | — | — | US | disclosed |
| US-20230147257-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | DONG-A ST CO., LTD. (KR) | 2023-05-11 | — | — | US | disclosed |
| US-20080269192-A1 | Chiral Fused [1,2]Imidazo[4,5-C] Ring Compounds | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080214654-A1 | Substituted Benzyloxy-Phenylmethylamide Derivatives | BAYER HEALTHCARE AG (DE) | 2008-09-04 | — | — | US | disclosed |
| EP-1831226-A2 | CHIRAL FUSED 1,2 IMIDAZO 4,5-c RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-09-12 | — | — | EP | disclosed |
| EP-1802600-A1 | SUBSTITUTED 4-BENZYLOXY-PHENYLMETHYLAMIDE DERIVATIVES AS COLD MENTHOL RECEPTOR-1 (CMR-1) ANTAGONITS FOR THE TREATMENT OF UROLOGICAL DISORDERS | Bayer HealthCare AG (DE) | 2007-07-04 | — | — | EP | disclosed |
| WO-2007017093-A1 | SUBSTITUTED 2-BENZYLOXY-BENZOIC ACID AMIDE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007017092-A1 | SUBSTITUTED 4-BENZYLOXY-BENZOIC ACID AMIDE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2007-02-15 | — | — | WO | disclosed |
| WO-2006074003-A2 | CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-07-13 | — | — | WO | disclosed |
| WO-2006040136-A1 | SUBSTITUTED 4-BENZYLOXY-PHENYLMETHYLAMIDE DERIVATIVES AS COLD MENTHOL RECEPTOR-1 (CMR-1) ANTAGONISTS FOR THE TREATMENT OF UROLOGICAL DISORDER | BAYER HEALTHCARE AG (DE) | 2006-04-20 | — | — | WO | disclosed |
| EP-1440052-B1 | BENZAMIDE DERIVATIVES AS ANTAGONISTS OF OREXIN RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2005-12-14 | — | — | EP | disclosed |